Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples

Biomedicine and Pharmacotherapy

Volumn 68, Issue 5, 2014, Pages 521-526

  Stankovic, Tijana ^a   Milinkovic, Vedrana ^a   Bankovic, Jasna ^a   Dinic, Jelena ^a   Tanic, Nasta ^b   Dramicanin, Tatjana ^b   Tanic, Nikola ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Breast carcinoma; Glioma; Non small cell lung carcinoma; P16; P53; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PTEN PROTEIN, HUMAN;

ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; COMPARATIVE STUDY; DNA FINGERPRINTING; GENOMIC INSTABILITY; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; LUNG SMALL CELL CANCER; METHYLATION; MICROSATELLITE INSTABILITY; MUTATION; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; BRAIN TUMOR; BREAST TUMOR; FEMALE; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; NON SMALL CELL LUNG CANCER;

BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, TUMOR SUPPRESSOR; GENOMIC INSTABILITY; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MUTATION; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905080503     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.03.014     Document Type: Article

References (38)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
3. Yeang C.H., McCormick F., Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J 2008, 22:2605-2622.
4. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
5. Li L., Ross A.H. Why is PTEN an important tumor suppressor?. J Cell Biochem 2007, 102:1368-1374.
6. Rocco J.W., Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001, 264:42-55.
7. Athanassiadou P., Athanassiades P., Grapsa D., et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer 2007, 17:697-704.
8. Hu T.H., Huang C.C., Lin P.R., et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003, 97:1929-1940.
9. Oki E., Tokunaga E., Nakamura T., et al. Genetic mutual relationship between PTEN and p53 in gastric cancer. Cancer Lett 2005, 227:33-38.
10. Andjelkovic T., Bankovic J., Stojsic J., et al. Co-alterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl Res 2011, 157:19-28.
11. Vonlanthen S., Heighway J., Tschan M.P., et al. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 1998, 17:2779-2785.
12. Karsai S., Abel U., Roesch-Ely M., et al. Comparison of p16 (INK4a) expression with p53 alterations in head and neck cancer by tissue microarray analysis. J Pathol 2007, 211:314-322.
13. Lee M., Sup Han W., Kyoung Kim O., et al. Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol Res Pract 2006, 202:415-424.
14. Taghavi N., Biramijamal F., Sotoudeh M., et al. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. BMC Cancer 2010, 10:138.
15. Andjelkovic T., Bankovic J., Milosevic Z., et al. Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients. Cancer Biomark 2011, 10:277-286.
16. Carrasco D.R., Fenton T., Sukhdeo K., et al. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell 2006, 9:379-390.
17. Beckman R.A., Loeb L.A. Genetic instability in cancer: theory and experiment. Semin Cancer Biol 2005, 15:423-435.
18. Milinkovic V., Bankovic J., Rakic M., et al. Genomic instability and p53 alterations in patients with malignant glioma. Exp Mol Pathol 2012, 93:200-206.
19. Bloom H.J.R.W. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957, 11:359-377.
20. Sambrook J. Purification of Nucleic Acids. Molecular cloning: a laboratory manual 1989, E.3-E.4. Cold Spring Harbor Laboratory Press, New York. Second ed. C. Nolan (Ed.).
21. Orita M., Iwahana H., Kanazawa H., Hayashi K., Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single strand conformation polymorphisms. Proc Natl Acad Sci U S A 1989, 86:2766-2770.
22. Hayashi Y., Iwato M., Arakawa Y., et al. Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. J Neurooncol 2001, 55:51-58.
23. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996, 93:9821-9826.
24. Zysman M.A., Chapman W.B., Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 2002, 160:795-800.
25. Markovic J., Stojsic J., Zunic S., Ruzdijic S., Tanic N. Genomic instability in patients with non-small cell lung cancer assessed by the arbitrarily primed polymerase chain reaction. Cancer Invest 2008, 26:262-268.
26. Bankovic J., Stojsic J., Jovanovic D., et al. Identification of genes associated with non-small-cell lung cancer promotion and progression. Lung Cancer 2010, 67:151-159.
27. Gorgoulis V.G., Zacharatos P., Kotsinas A., et al. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol 1998, 153:1749-1765.
28. Ihde D.C., Minna J.D. Non-small cell lung cancer. Part I: Biology, diagnosis, and staging. Curr Probl Cancer 1991, 15:61-104.
29. Ishii N., Maier D., Merlo A., et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999, 9:469-479.
30. Kim H.S., Woolard K., Lai C., et al. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. Cancer Res 2012, 72:6065-6075.
31. Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007, 170:1445-1453.
32. Emig R., Magener A., Ehemann V., et al. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 1998, 78:1661-1668.
33. Radpour R., Barekati Z., Haghighi M.M., et al. Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. Mod Pathol 2010, 23:763-772.
34. Zhang J., Pickering C.R., Holst C.R., Gauthier M.L., Tlsty T.D. p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res 2006, 66:10325-10331.
35. Stambolic V., Tsao M.S., Macpherson D., Suzuki A., Chapman W.B., Mak T.W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 2000, 60:3605-3611.
36. Kurose K., Gilley K., Matsumoto S., Watson P.H., Zhou X.P., Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002, 32:355-357.
37. Jones N., Bonnet F., Sfar S., et al. Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer 2013, 133:323-334.
38. Backlund L.M., Nilsson B.R., Goike H.M., et al. Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 2003, 9:4151-4158.